How Compounding Pharmacy Helps Prescribers Close the 50% Adherence Gap

Introduction: The Adherence Gap Hiding in Plain Sight

For certain medication classes, standard dosing approaches fail to achieve optimal therapeutic outcomes in up to 50% of patients. That is only half of the problem. Nearly half of all patients also fail to adhere to prescribed therapies, which leads to unnecessary complications, hospitalizations, and billions of dollars in avoidable healthcare costs.

These two figures describe a gap that most prescribers manage every day, often without naming it. The useful question is not simply “how does a prescriber vet a compounding pharmacy?” It is “what measurable clinical and business problem does compounding actually solve?”

This article looks at the answer through two lenses. The first is clinical: dosing precision, delivery form, and pill burden. The second is operational: practice differentiation, patient retention, and fewer call-backs. Together, they show how compounding pharmacy helps prescribers address both the dosing gap and the adherence gap.

The Two Gaps Every Prescriber Is Already Managing

Non-adherence and suboptimal dosing are related, but they are distinct problems. A patient can take a medication exactly as directed and still receive the wrong strength for their biology. Another patient can receive the ideal strength and never take it consistently. Compounding can address both, and the clinical reasoning in the rest of this article builds on that distinction.

The Dosing Gap: When Standard Strengths Aren’t Enough

Commercial medications come in fixed strengths. Real patients vary widely in metabolism, drug sensitivity, body weight, age, and comorbidities. When standard dosing falls short for up to half of patients in certain medication classes, individualized titration becomes a clinical necessity rather than a preference.

Common examples include:

• Hormone therapy, where dosing is adjusted against lab values over time.
• Pediatric care, where dosing is based on weight and a child’s needs rarely line up with adult tablet strengths.
• Pain management, where effective relief may require non-standard strengths or concentrations.

The Adherence Gap: When the Right Drug Isn’t Taken the Right Way

When nearly half of patients do not follow prescribed therapy, the consequences build on each other: avoidable complications, hospital admissions, wasted follow-up visits, and preventable healthcare spending.

The barriers behind non-adherence tend to be practical:

• Pill burden from multi-drug regimens
• Taste and palatability, especially in children
• Difficulty swallowing tablets or capsules
• Allergies and sensitivities to dyes, fillers, or preservatives
• Inconvenient delivery forms, such as a greasy ointment a patient simply won’t apply

Most of these are formulation problems, not willpower problems. Seen this way, adherence becomes a design issue that prescribers can influence directly.

Why Standard, Mass-Produced Dosing Falls Short

Commercial drug manufacturing is built for scale. Fixed strengths and standardized forms are designed around population averages, and that design makes sense for mass production and regulatory approval. Clinical practice, however, involves individuals whose response, tolerance, and lifestyle constraints differ from the statistical middle.

Compounding bridges population-level manufacturing and patient-level care. Research published in PubMed Central, “The Role of Pharmaceutical Compounding in Promoting Medication Adherence,” describes compounding as an integral part of pharmacy practice and essential to the provision of healthcare. Its value lies in adapting a medication to the patient rather than asking the patient to adapt to the medication.

How Compounding Pharmacy Closes the Gap: Core Clinical Capabilities

Compounding addresses the dosing gap and the adherence gap through four core capabilities. Each one corresponds to a specific failure point in standard therapy.

Dose Titration and Personalized Strengths

Compounding pharmacies can adjust strength and formulation at each refill based on lab results or clinical response. Bioidentical hormone replacement therapy (BHRT) is the clearest example, since formulas can be refined as a patient’s labs change.

Compounding pharmacists also support prescribers with technical clinical calculations. These include potency adjustments, isotonicity and osmolarity for sterile products, capsule formulations, and suppository or lozenge dosing. That support reduces prescriber workload and lowers the risk of formulation errors.

Demand for this kind of titration is rising. Hormonal disorder diagnoses have increased by 15% year over year, fueling interest in individualized protocols.

Combination Dosing to Reduce Pill Burden

Compounding pharmacies can combine multiple active ingredients into a single dose. A topical pain preparation, for example, might combine an NSAID, a muscle relaxant, and a neuropathic agent in one cream instead of requiring three separate products.

Fewer products mean fewer steps, fewer missed doses, and a regimen that is easier to follow. For patients on complex therapies, simplification is one of the most direct routes to better adherence.

This approach also supports responsible pain management. Localized combination topicals deliver effect at the site of pain with minimized systemic absorption, which supports non-opioid or reduced-opioid prescribing strategies.

Alternative Delivery Forms That Patients Actually Use

A medication works only if the patient is willing and able to take it. Compounded delivery forms remove common barriers:

• Orodispersible tablets for patients who struggle to swallow
• Troches and lozenges for easier or sublingual administration
• Topical creams and gels for patients who prefer a lotion-like texture over an ointment

Clinical literature notes that compounded medications may improve adherence, including for topical therapy, such as when a patient prefers a lotion to an ointment or adheres better with an orodispersible tablet.

Practical applications span patient groups: flavored liquids and popsicles for children, sublingual troches for adults who need simpler administration, and topical formulations for BHRT and localized pain relief.

Allergen-, Dye-, and Filler-Free Formulations

Commercial medications often contain inactive ingredients such as dyes, gluten, lactose, and preservatives. For sensitive patients, these can trigger adverse reactions.

This is both a safety issue and an adherence issue. Patients who experience discomfort or reactions often stop taking a medication, sometimes without telling their prescriber. Allergen-free compounding removes the problem ingredient while keeping the therapy. Pediatric and dermatology patients benefit most, since both groups frequently include people with heightened sensitivities.

Specialty Use Cases Where Compounding Moves the Adherence Needle

Specialty applications are often discussed separately across different sources. The summary below groups them into a single prescriber-facing reference, each framed around a specific failure point.

Bioidentical Hormone Replacement Therapy (BHRT)

Failure point: Fixed commercial hormone strengths rarely match an individual’s lab-confirmed needs.

Compounding solution: BHRT dosing adjusted against lab results at each refill directly targets the dosing gap for menopause and andropause patients. As hormonal disorder diagnoses continue to rise year over year, demand for this personalized approach continues to grow.

Pain Management and Opioid-Sparing Strategies

Failure point: Systemic side effects discourage consistent use and can push treatment toward stronger systemic agents.

Compounding solution: Localized combination topicals reduce systemic exposure and support reduced-opioid treatment plans. Fewer side effects also encourage patients to use their therapy consistently.

Pediatrics

Failure point: Taste and swallowing difficulty are two of the most common pediatric adherence barriers.

Compounding solution: Age- and weight-specific dosing, combined with flavor customization, addresses both. Research on pediatric compounding in PubMed Central notes that clinical compounding pharmacists can guide the choice of dosage form, dose, and formulation for individual children.

Sports Medicine

Failure point: Performance-focused patients often resist therapies that cause systemic side effects or interfere with training.

Compounding solution: Personalized formulations support recovery and inflammation management with fewer systemic effects, which appeals to patients who prioritize function and tolerability.

The 2026 Regulatory Backdrop Prescribers Should Understand

Regulatory context matters because quality and compliance shape clinical outcomes. This section is meant to explain that context, not to serve as a compliance checklist.

503A vs. 503B: Why the Distinction Affects Clinical Use

• 503A pharmacies compound patient-specific prescriptions under state pharmacy law. This is the traditional compounding model.
• 503B outsourcing facilities are FDA-registered and may produce larger batches for office use without patient-specific prescriptions.

In practice, the distinction shapes how a medication reaches the patient. Take-home prescriptions for individual patients generally go through 503A pharmacies, while stock for in-office administration generally comes from 503B facilities.

The Shifting GLP-1 and Drug Shortage Landscape

The FDA resolved the tirzepatide shortage in December 2024 and the semaglutide shortage in February 2025, which ended the shortage-based compounding exemptions. In April 2026, the FDA reiterated that compounders must meet strict “essentially a copy” and patient-specific documentation conditions under Sections 503A and 503B. On April 30, 2026, the agency proposed permanently excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list. That proposal would close the last large-scale outsourcing pathway for these drugs, although 503A patient-specific compounding is not directly affected.

Compounding remains relevant beyond GLP-1s. ASHP identified 89 new drug shortages in 2025, the lowest annual total since 2006. Active shortages nonetheless rose to 227 by the second quarter of 2026, the third consecutive quarterly increase.

Because compounded drugs are not FDA-approved, prescribers carry documentation responsibility. The FDA has not fully specified what records justify a “significant difference” from a commercial product, so prescribers should discuss documentation practices with their pharmacy partner.

Quality Standards That Underpin Safe Personalization

USP chapters <795> (non-sterile), <797> (sterile), and <800> (hazardous drugs) all became enforceable by November 2023. Revised PCAB standards incorporating those updates took effect in June 2024.

Fewer than 1% of the roughly 7,500 U.S. compounding pharmacies hold PCAB accreditation, and the American Medical Association recommends that physicians use only PCAB-accredited compounding pharmacies. For prescribers, that recommendation offers a clear quality benchmark.

The Business Case: What Closing the Adherence Gap Means for a Practice

Compounding is a clinical tool, and it is also an operational and competitive lever for a practice.

Fewer Call-Backs, Fewer Complications

More precise dosing and better adherence lead to fewer follow-up calls, fewer complaints that a medication “isn’t working,” and fewer adverse reactions. With nearly half of patients non-adherent, even modest improvements can reduce downstream complications and the administrative burden that comes with them.

Patient Retention and Practice Differentiation

Personalized flavors, forms, and combination doses create a patient experience that practices relying only on commercial drugs cannot replicate. Some practices develop signature protocols, such as a proprietary BHRT titration approach or a branded pediatric flavor system, that patients come to associate with that specific practice.

This is not a fringe strategy. Hospitals and clinics now account for roughly 40 to 50% of the U.S. compounding end-user market.

A Growing, Increasingly Mainstream Market

The U.S. compounding pharmacy market is projected to grow from about $7 billion in 2025 and 2026 to $12.79 billion by 2035, a compound annual growth rate of roughly 6.24%. The main drivers are chronic disease burden, an aging population, and ongoing drug shortages, all of which prescribers encounter daily. Compounding is moving from a niche service toward a standard-of-care adjunct, particularly in hospital and clinic settings.

What a Strong Compounding Partnership Looks Like in Practice

Clinical benefits only matter if they can be delivered reliably. Nationwide Compounding Rx® offers one example of a structured, prescriber-facing model through its Connect → Collaborate → Create → Care framework.

Operational details that support adherence and retention include:

• 1 to 2 business day turnaround, with same-day pickup available for some medications
• Nationwide shipping, subject to medication type and state licensing
• Secure provider and patient portals for submitting prescriptions, tracking orders, and managing refills
• PCAB accreditation and USP 800 compliance, supported by independent third-party testing and sourcing from FDA-inspected vendors

This infrastructure is what allows titration, combination dosing, and alternative delivery forms to work consistently across an entire patient panel.

Conclusion: Turning a Clinical Gap Into a Practice Advantage

The up-to-50% suboptimal dosing rate and the near-50% non-adherence rate are two sides of the same solvable problem. Titration, combination dosing, alternative delivery forms, and allergen-free formulations target both. For a practice, the results include fewer call-backs, stronger patient retention, and clear differentiation in a growing, increasingly mainstream market. Seen this way, compounding is less a last resort and more a strategic clinical and operational partner.

Partner With a Pharmacy Built for Clinical Precision and Practice Growth

Prescribers who want to explore personalized formulations for BHRT, pediatrics, pain management, or sports medicine can start with a conversation. Nationwide Compounding Rx® begins every provider relationship with the Connect → Collaborate → Create → Care framework.

Next step: Visit the Provider Portal at nationwidecompounding.com, submit a request through the contact form, or call (480) 499-8379 to discuss formulation options for their practice.